Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senomyx

This article was originally published in The Tan Sheet

Executive Summary

La Jolla, Calif.-based Senomyx will work with Tokyo-based food and culinary product firm Ajinomoto to develop "specific natural flavor ingredients" over a three-year period, under the terms of a second research and commercialization agreement announced Oct. 11. Additionally, the U.S. Patent & Trademark Office issued Senomyx a patent for human bitter taste receptors shown to be activated by artificial sweeteners saccharin and acesulfame potassium, Senomyx says in a Sept. 26 release. The receptors will be used by the firm to screen for new flavor ingredients capable of blocking the bitter taste associated with these sweetners. Senomyx is also looking to use its bitter-blocking technology in the pharmaceutical arena (1"The Tan Sheet" Jan. 16, 2006, p. 13)...

You may also be interested in...



Senomyx Seeks Alternatives To “Spoonful Of Sugar” To Make Meds Go Down

Senomyx expects to develop bitter flavor-blocking agents for use in pediatric OTC products in 2006, the biotechnology firm stated during a Jan. 12 presentation to investors

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Topics

UsernamePublicRestriction

Register

PS099857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel